rs1532085 — LIPC

LIPC rs1532085 — When Higher HDL Does Not Mean the Same Thing for Everyone

Your liver's hepatic lipase (HL) enzyme is a key player in the final remodeling of lipoprotein particles. After peripheral tissues strip triglycerides from VLDL using lipoprotein lipase, the remnant particles — along with mature HDL2 — arrive at the liver surface where hepatic lipase hydrolyzes their remaining triglycerides and phospholipids. This converts large, buoyant HDL2 into smaller, denser HDL3 particles and clears IDL particles back into the LDL pool. HL is therefore central to HDL particle composition, not just the total HDL-C number on a standard lipid test. The rs1532085 variant on chromosome 15q22 sits in the 5' regulatory region of the LIPC gene and acts as an expression quantitative trait locus (eQTL)¹¹ expression quantitative trait locus (eQTL)
a variant that influences how much of a gene product the cell makes, rather than changing the protein itself. The minor A allele is associated with reduced LIPC expression in the liver, leading to lower hepatic lipase activity — with downstream consequences for HDL composition, triglyceride clearance, and cardiovascular risk that are more nuanced than the total HDL-C figure suggests.

The Mechanism

With reduced hepatic lipase activity from one or two A alleles, the remodeling pipeline slows at the liver surface. Large, cholesterol-rich HDL2 particles accumulate in circulation because they are not being efficiently converted to HDL3. This is why A allele carriers show higher total HDL-C on a standard lipid panel — they are retaining more of the large HDL2 subclass, not producing more of the small, efficient HDL3 particles that pick up cholesterol from arterial walls. Simultaneously, reduced HL activity slows the clearance of IDL and VLDL remnants. Triglyceride levels tend to rise in proportion to the number of A alleles carried, creating a dual phenotype: higher nominal HDL-C alongside higher triglycerides — a pattern that looks better on a standard lipid panel than it actually is for cardiovascular risk. The rs1532085 A allele functions in the same directional pathway as the well-characterized LIPC promoter variants rs1800588 (-514C>T) and rs2070895 (-250G>A), which are in moderate to high linkage disequilibrium with this locus. Genetic tests may report any of these variants; their effects on hepatic lipase expression are mechanistically convergent.

The Evidence

The clearest GWAS signal comes from the Teslovich et al. 2010 meta-analysis²² Teslovich et al. 2010 meta-analysis of more than 100,000 individuals of European ancestry, which identified rs1532085 near LIPC as one of 95 genome-wide significant lipid loci, reaching P=9.7×10⁻³⁶ for HDL-C association. This places the LIPC locus among the most robustly established HDL-C-modifying genomic regions in humans. A knowledge-driven multi-ethnic interaction study³³ knowledge-driven multi-ethnic interaction study identified a gene-gene interaction between the LIPC (rs1532085) and HMGCR regions affecting HDL-C, with the interaction explaining 0.2–1.1% additional HDL-C variance across replication cohorts. A follow-up eQTL analysis⁴⁴ follow-up eQTL analysis characterized rs1532085 as an eQTL hub for LIPC expression, showing it explains 0.65% of HDL-C variance alone, with an additional 1.4% through gene-gene interactions. In the RCG discovery cohort of 2,091 European Americans, individuals homozygous for the minor allele at both rs1532085 and the interacting SNP rs12980554 showed the highest HDL-C levels (43±5.9 mg/dL vs cohort mean of 38.5±7.1 mg/dL), consistent with progressive reduction in hepatic lipase activity amplified by the gene-gene interaction. In a Chinese cohort of 1,634 Han and Maonan participants⁵⁵ Chinese cohort of 1,634 Han and Maonan participants, the A allele was associated with elevated triglycerides — and in Han females specifically with lower total cholesterol, LDL-C, and ApoA1 — suggesting both sex-specific and population-specific expression of these effects. A Taiwanese study of 572 adults⁶⁶ Taiwanese study of 572 adults found that rs1532085 A allele carriers had significantly higher triglycerides and elevated urinary 8-hydroxy-deoxyguanosine (8-OHdG), a validated marker of oxidative DNA damage, independent of HDL-C or triglyceride adjustment — pointing to a pleiotropic role of this LIPC regulatory variant beyond lipid metabolism alone. The gene-diet interaction evidence from the closely related LIPC promoter haplotype (documented in the Framingham Heart Study, 2,130 subjects⁷⁷ Framingham Heart Study, 2,130 subjects) shows that at lower dietary fat intakes, the A allele's HDL-raising effect is preserved. At higher intakes of saturated and monounsaturated fat (≥30% of calories from total fat), the HDL advantage diminishes or reverses — TT individuals in the LD haplotype showed the lowest HDL-C at high fat intakes. Polyunsaturated fat did not trigger the same interaction.

Practical Actions

For GG homozygotes (most common genotype in Europeans, ~40%), hepatic lipase activity is at the reference level. HDL-C tends to be at typical population levels. Standard lipid management applies, and there is no genotype-specific dietary fat sensitivity at this locus. For AG heterozygotes (~46% of Europeans), one A allele moderately reduces hepatic lipase expression. HDL-C is likely mildly elevated while triglycerides may trend higher. Monitoring both values together gives a more accurate picture than HDL-C alone. Keeping saturated fat intake moderate helps preserve the HDL advantage. For AA homozygotes (~14% of Europeans), two A alleles substantially reduce hepatic lipase expression, producing the highest HDL-C in this genotype class alongside elevated triglycerides. The elevated HDL-C reading reflects accumulation of large HDL2 particles from impaired HL remodeling — not necessarily more efficient reverse cholesterol transport. A diet emphasizing polyunsaturated omega-3 fats while limiting saturated fat below 10% of calories preserves the HDL benefit and counters the triglyceride elevation. Direct particle-level HDL testing (NMR lipoprofile or apolipoprotein A-I measurement) provides more reliable cardiovascular risk information than total HDL-C in this genotype.

Interactions

rs1532085 is in moderate to high linkage disequilibrium with the LIPC promoter haplotype variants rs1800588 (-514C>T), rs2070895 (-250G>A), rs1077835 (-763A>G), and rs1077834 (-710C>T). Genetic tests reporting any one of these will largely capture the same underlying effect on hepatic lipase expression. When a test reports multiple LIPC variants and they appear discordant, rs1532085 as the GWAS lead SNP is the better-powered estimate of the regulatory effect. A gene-gene interaction between rs1532085 and HMGCR (the statin target enzyme) affects HDL-C levels in European and multi-ethnic populations. Carriers of the rs1532085 A allele who also carry certain HMGCR variants may see amplified or attenuated HDL effects beyond what either variant predicts alone. This interaction is described in the rs1532085–HMGCR interaction literature and is a candidate for a compound action pairing these loci. CETP gene variants (particularly rs708272) interact additively with LIPC variants to raise HDL-C, but studies show only the CETP side of the interaction appears to translate to reduced coronary artery disease events — a reminder that nominally higher HDL-C from HL deficiency and higher HDL-C from efficient reverse cholesterol transport carry different cardiovascular implications.